Back

Safety, pharmacodynamic and pharmacokinetic characterisation of vericiguat: key results from six phase I studies in healthy subjects

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Other HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Corina Becker

Bayer AG, Wuppertal (Germany)

12 More presentations in this session

Presentation thumbnail
Optimal administration timing of thiazide diuretics for sequential nephron blockade in cardiovascular patients receiving loop diuretics
Doctor J. Fallon (Cleveland, US)
Abstract Slides
Presentation thumbnail
Super-response to sacubitril valsartan: prevalence and clinical profile
Mr C. Moliner-Abos (Barcelona, ES)
Abstract
Presentation thumbnail
Who ARNI the best responders among patients with LVEF<35%?
Doctor J. De Almeida (Coimbra, PT)
Abstract
Presentation thumbnail
Rationale, design and baseline characteristics of the Personalised prospective comparison of ARni with ArB in patients with natriuretic peptide eLEvation (PARABLE) randomized controlled trial
Professor M. Ledwidge (Dublin, IE)
Abstract
Presentation thumbnail
Effect of empagliflozin on hydroelectrolytic balance in patients with heart failure with reduced ejection fraction
Doctor S. Del Prado Diaz (Madrid, ES)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Pharmacology and Pharmacotherapy

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources